DK2588488T3 - Jern (iii) caseinsuccinylat og fremgangsmåde til fremstillingen deraf - Google Patents
Jern (iii) caseinsuccinylat og fremgangsmåde til fremstillingen deraf Download PDFInfo
- Publication number
- DK2588488T3 DK2588488T3 DK10747311.8T DK10747311T DK2588488T3 DK 2588488 T3 DK2588488 T3 DK 2588488T3 DK 10747311 T DK10747311 T DK 10747311T DK 2588488 T3 DK2588488 T3 DK 2588488T3
- Authority
- DK
- Denmark
- Prior art keywords
- casein
- iron
- weight
- iii
- caseinsuccinylate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4732—Casein
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (16)
1. Jern (III) caseinsuccinylat kendetegnet ved et indhold afjern omfattende mellem 4,5 og 7 vægtprocent, ved en opløselighed større end ca. 92% og ved at have et phosphor/nitrogenforhold større end 5 vægtprocent, fortrinsvis større end ca. 5,5 vægtprocent.
2. Jern (III) caseinsuccinylat ifølge krav 1, kendetegnet ved at det indeholder en mængde proteinurenheder mindre end ca. 15 vægtprocent, fortrinsvis mindre end ca. 10 vægtprocent.
3. Fremgangsmåde til fremstilling afjern (III) caseinsuccinylat ifølge kravene 1 til 2, omfattende følgende trin: a. omsætte casein og succinsyreanhydrid i vand for at opnå succinyleret casein, b. omsætte succinyleret casein med jern (III) chlorid for at opnå jern (III) caseinsuccinylat, c. kendetegnet ved at caseinet ifølge trin a) er oprenset casein, med et proteinurenhedsindhold mindre end 15 vægtprocent og/eller uorganisk indhold af urenheder på mindre end 1 vægtprocent og/eller et phosphor-/nitrogenforhold større end 5%.
4. Fremgangsmåde ifølge krav 3, kendetegnet ved at af indholdet af proteinurenheder er mindre end ca. 10 vægtprocent og/eller det uorganiske indhold af urenheder er mindre end ca. 0,4 vægtprocent.
5. Fremgangsmåde ifølge krav 3, kendetegnet ved at proteinurenhederne er proteiner forskellige fra alfa-Sl-casein, alfa-S2-casein, betacasein, kappacasein, pseudo-kappacasein.
6. Fremgangsmåde ifølge krav 3, kendetegnet ved at det oprensede casein har et phosphor/nitrogenforhold større end ca. 5 vægtprocent.
7. Fremgangsmåde ifølge krav 3, kendetegnet ved at det oprensede casein opnås fra syrecasein eller osteløbe-casein.
8. Fremgangsmåde ifølge krav 3, omfattende et yderligere trin til mikrofiltrering af den vandige opløsning afjern (III) caseinsuccinylat.
9. Farmaceutisk sammensætning indeholdende jern (III) caseinsuccinylat ifølge kravene 1 til 2 og mindst én fysiologisk acceptabel excipiens.
10. Sammensætning ifølge krav 9, kendetegnet ved at det er i flydende eller fast form, fortrinsvis i flydende form.
11. Sammensætning ifølge krav 10, kendetegnet ved at den flydende form er en opløsning eller en suspension, fortrinsvis en vandig opløsning.
12. Sammensætning ifølge krav 9 kendetegnet ved at den flydende sammensætning er en opløsning indeholdende ca. 8 vægtprocent afjern (III) caseinsuccinylat med en viskositet mindre end ca. 400 mPa-sec, fortrinsvis mindre end ca. 300 mPa-sec.
13. Sammensætning ifølge et hvilket som helst af kravene 9 til 12, hvor jern (III) caseinsuccinylat er indeholdt ved en mængde bestående mellem 5 og 15 vægtprocent, fortrinsvis mellem 6 og 12 vægtprocent, mere fortrinsvis mellem 7 og 9 vægtprocent, i forhold til sammensætningens totalvægt.
14. Sammensætning ifølge et hvilket som helst af kravene 9 til 13 til oral eller parenteral anvendelse, fortrinsvis til oral anvendelse.
15. Sammensætning ifølge et hvilket som helst af kravene 9 til 14, til anvendelse i behandlingen af jernmangel.
16. Sammensætning til anvendelse ifølge krav 15, i behandlingen af anæmi, graviditetsjernmangel, malabsorptions-syndrom, jernmangel under amning og jernmangel under vækst.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IT2010/000287 WO2012001712A1 (en) | 2010-06-30 | 2010-06-30 | Iron (iii) caseinsuccinylate and method for the preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2588488T3 true DK2588488T3 (da) | 2017-04-03 |
Family
ID=43302532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10747311.8T DK2588488T3 (da) | 2010-06-30 | 2010-06-30 | Jern (iii) caseinsuccinylat og fremgangsmåde til fremstillingen deraf |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20130102529A1 (da) |
| EP (1) | EP2588488B1 (da) |
| KR (1) | KR101701830B1 (da) |
| CN (2) | CN103025751B (da) |
| AR (1) | AR122394A2 (da) |
| BR (1) | BR112012032364B1 (da) |
| CY (1) | CY1119054T1 (da) |
| DK (1) | DK2588488T3 (da) |
| ES (1) | ES2628306T3 (da) |
| HR (1) | HRP20170541T1 (da) |
| HU (1) | HUE032746T2 (da) |
| LT (1) | LT2588488T (da) |
| MA (1) | MA34319B1 (da) |
| MX (1) | MX346317B (da) |
| PL (1) | PL2588488T3 (da) |
| PT (1) | PT2588488T (da) |
| RS (1) | RS55978B1 (da) |
| RU (1) | RU2533826C2 (da) |
| SI (1) | SI2588488T1 (da) |
| WO (1) | WO2012001712A1 (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102836419B (zh) * | 2012-09-25 | 2014-06-25 | 济川药业集团有限公司 | 一种蛋白琥珀酸铁口服溶液及其制备方法 |
| CN108498454B (zh) * | 2018-04-03 | 2020-11-06 | 济川药业集团有限公司 | 一种蛋白琥珀酸铁口服液及其制备方法 |
| CN111000977A (zh) * | 2019-03-22 | 2020-04-14 | 江苏中天药业有限公司 | 一种蛋白琥珀酸铁固体新剂型及其制备方法 |
| CN112063676B (zh) * | 2020-09-02 | 2021-11-12 | 杭州汉库医药科技有限公司 | 酪蛋白纯化方法和蛋白琥珀酸铁的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1150213B (it) | 1982-03-02 | 1986-12-10 | Italfarmaco Spa | Derivati di ferro biodisponibile esenti da gastrolesivita',procentimento di preparazione e relative composizioni farmaceutiche |
| IT1222912B (it) | 1987-10-14 | 1990-09-12 | Italfarmaco Spa | Derivati polipeptidici a elevato tenore di ferro e altamente solubili atti alla terapia marziale procedimenti di preparazione e loro forme farmaceutiche |
| IT1297022B1 (it) * | 1997-12-24 | 1999-08-03 | Chemi Spa | Complesso di ferro-succinilcaseina, processo per la sua preparazione e composizioni farmaceutiche che lo contengono |
| ITMO20040200A1 (it) * | 2004-07-29 | 2004-10-29 | Biofer Spa | Processo per la produzione di complessi ferro succinilcaseina e ferro casein acetil aspartilato e loro utilizzato nelle relative composizioni farmaceutiche. |
| NZ568332A (en) * | 2005-12-06 | 2010-11-26 | Vifor Int Ag | Process for the preparation of ferri-succinylcasein |
| WO2007143088A2 (en) * | 2006-06-02 | 2007-12-13 | Abbott Laboratories | Protein ingredient with improved sensory quality and nutritionals with improved flavor containing same |
| TWI346666B (en) * | 2007-12-31 | 2011-08-11 | Animal Technology Inst Taiwan | Method for seperating casein from casein-contained solution |
-
2010
- 2010-06-30 BR BR112012032364-4A patent/BR112012032364B1/pt active IP Right Grant
- 2010-06-30 KR KR1020137000100A patent/KR101701830B1/ko active IP Right Grant
- 2010-06-30 HU HUE10747311A patent/HUE032746T2/en unknown
- 2010-06-30 PT PT107473118T patent/PT2588488T/pt unknown
- 2010-06-30 RS RS20170339A patent/RS55978B1/sr unknown
- 2010-06-30 EP EP10747311.8A patent/EP2588488B1/en active Active
- 2010-06-30 ES ES10747311.8T patent/ES2628306T3/es active Active
- 2010-06-30 PL PL10747311T patent/PL2588488T3/pl unknown
- 2010-06-30 CN CN201080067086.XA patent/CN103025751B/zh active Active
- 2010-06-30 US US13/805,545 patent/US20130102529A1/en not_active Abandoned
- 2010-06-30 MA MA35466A patent/MA34319B1/fr unknown
- 2010-06-30 DK DK10747311.8T patent/DK2588488T3/da active
- 2010-06-30 CN CN201611051501.8A patent/CN107090011A/zh active Pending
- 2010-06-30 SI SI201031456A patent/SI2588488T1/sl unknown
- 2010-06-30 RU RU2013103799/04A patent/RU2533826C2/ru active
- 2010-06-30 MX MX2012014199A patent/MX346317B/es active IP Right Grant
- 2010-06-30 LT LTEP10747311.8T patent/LT2588488T/lt unknown
- 2010-06-30 WO PCT/IT2010/000287 patent/WO2012001712A1/en active Application Filing
-
2017
- 2017-04-03 HR HRP20170541TT patent/HRP20170541T1/hr unknown
- 2017-06-08 CY CY20171100609T patent/CY1119054T1/el unknown
-
2021
- 2021-03-15 AR ARP210100656A patent/AR122394A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2013103799A (ru) | 2014-08-10 |
| MX346317B (es) | 2017-03-15 |
| KR101701830B1 (ko) | 2017-02-13 |
| RS55978B1 (sr) | 2017-09-29 |
| LT2588488T (lt) | 2017-05-10 |
| BR112012032364A2 (pt) | 2016-10-04 |
| HUE032746T2 (en) | 2017-10-30 |
| HRP20170541T1 (hr) | 2017-06-16 |
| CY1119054T1 (el) | 2018-01-10 |
| MA34319B1 (fr) | 2013-06-01 |
| CN103025751B (zh) | 2016-12-21 |
| PT2588488T (pt) | 2017-06-26 |
| CN107090011A (zh) | 2017-08-25 |
| KR20130136422A (ko) | 2013-12-12 |
| AR122394A2 (es) | 2022-09-07 |
| RU2533826C2 (ru) | 2014-11-20 |
| CN103025751A (zh) | 2013-04-03 |
| MX2012014199A (es) | 2013-05-06 |
| SI2588488T1 (sl) | 2017-07-31 |
| WO2012001712A1 (en) | 2012-01-05 |
| EP2588488A1 (en) | 2013-05-08 |
| EP2588488B1 (en) | 2017-03-15 |
| ES2628306T3 (es) | 2017-08-02 |
| BR112012032364B1 (pt) | 2021-08-31 |
| PL2588488T3 (pl) | 2017-09-29 |
| US20130102529A1 (en) | 2013-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2588488T3 (da) | Jern (iii) caseinsuccinylat og fremgangsmåde til fremstillingen deraf | |
| KR102593901B1 (ko) | 제약-등급 20-히드록시엑디손 추출물, 그의 용도 및 그의 제법 | |
| Leonil et al. | Kinetics of fibril formation of bovine κ-casein indicate a conformational rearrangement as a critical step in the process | |
| CN104284662A (zh) | 晶体及包含该晶体的药物制剂 | |
| KR20170038085A (ko) | 알로에 다당류의 조성물 및 방법 | |
| WO2013051483A1 (ja) | 植物からポリアミン組成物を製造する方法 | |
| KR101893964B1 (ko) | 클로로겐산 결정형 및 이의 제조 방법 | |
| JP2002521340A (ja) | 有機溶媒含有または非含有溶液を利用した軟骨部抽出物を得る方法およびそれから分離された抽出物 | |
| CN109369783A (zh) | 一种多肽rdp1及其提纯方法与应用 | |
| JP6662503B2 (ja) | ポリ硫酸ペントサン及びポリ硫酸ペントサンを含む医薬 | |
| TWI542357B (zh) | 植物萃取物及治療肝臟纖維化與肝癌之方法 | |
| CN117843645A (zh) | 一种pde9抑制剂的一水合物和结晶形态 | |
| JP6738350B2 (ja) | 尿酸輸送体阻害剤のナトリウム塩およびその結晶形 | |
| CN116869853A (zh) | 鲟鱼籽肽粉及其制备方法、化妆品组合物 | |
| WO1983003198A1 (en) | A method for dividing blood hemoglobin into heme and globin | |
| EP2889037B1 (en) | Plant extract and the process for treating hepatic fibrosis and liver cancer | |
| CN109517031B (zh) | 一种寡肽化合物及其制备方法和用途 | |
| EP3571935A1 (en) | Dried egg-white production method and dried egg-white | |
| JP2018193346A (ja) | Ｔｉｅ２活性化組成物及びその製造方法 | |
| WO2012021076A2 (en) | A method of extracting lectin from the common bean as well as a lectin preparation | |
| JP2003026610A (ja) | イヌリン含有製剤 | |
| US20220273706A1 (en) | Composition and Method for treatment of diabetes | |
| JP2022181178A (ja) | α－シヌクレインの凝集抑制剤、シヌクレオパチーの治療または予防剤、アミロイド形成疾患の治療または予防剤 | |
| CN107929349A (zh) | 一种天花粉注射制剂药物组合物的制备方法 | |
| CN107951919A (zh) | 一种天花粉的注射用药物组合物 |